ArticleInternational journal of chronic obstructive pulmonary disease2026
ADAMTS5 May Serve as a Useful Biomarker for Chronic Obstructive Pulmonary Disease.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A disintegrin-like and metalloprotease with thrombospondin type I repeats 5 (ADAMTS5) is related to inflammation and regulates the extracellular matrix. This study aimed to investigate the plasma ADAMTS5 levels and the correlations between ADAMTS5 and pulmonary function parameters in patients with chronic obstructive pulmonary disease (COPD) and to test the efficiency of ADAMTS5 for COPD diagnosis. Methods: Seventy-nine patients with COPD and 36 healthy subjects were recruited. The plasma ADAMTS5 levels of all subjects were detected by ELISA. The correlations between ADAMTS5 and pulmonary function parameters were analyzed. The multiple linear regression analysis with stepwise selection was used to explore the relationship between ADAMTS5 and pulmonary function parameters. Receiver-operating characteristic (ROC) curve was used to investigate the role of ADAMTS5 in the diagnosis of COPD. Results: All patients with COPD were divided into acute exacerbation of COPD (AECOPD) group (n=45) and stable COPD (S-COPD) group (n=34). Additionally, healthy subjects were included in control group (n=36). Plasma ADAMTS5 levels in AECOPD or S-COPD groups were significantly higher than those in control group (83.49±17.10ng/mL vs 61.59±15.33ng/mL, p<0.001; 69.87±11.84ng/mL vs 61.59±15.33ng/mL, p=0.014, respectively). In addition, plasma ADAMTS5 levels in AECOPD group were significantly higher than in S-COPD group (p<0.001). Meanwhile, the ADAMTS5 was negatively correlated with FVC%, FEV1%, FEV1/FVC%, PEF%, or FEF25-75%. Importantly, the ADAMTS5 was associated with FVC% and FEV1/FVC%. In addition, the area under the ROC curve (AUC) of ADAMTS5 for the diagnosis of COPD was 0.789 and the optimal threshold was 63.22ng/mL, exhibiting the sensitivity and specificity of 83.54% and 75.00%, respectively. Moreover, the ADAMTSS5 was an independent risk factor for COPD. Conclusion: The level of plasma ADAMTS5 is increased and independently associated with FVC% and FEV1/FVC% in COPD. The ADAMTS5 exhibits moderate diagnostic accuracy in COPD. The ADAMTS5 has the potential to serve as a promising biomarker for COPD diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.